A Study Of AAVB-039 In Participants With Stargardt Disease (STGD1)

Overview

About this study

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Molecular diagnosis of Stargardt disease due to ABCA4 mutation
* Willingness to adhere to protocol per informed consent

Exclusion Criteria:

* Unwillingness to meet the requirements of the study
* Participation in a clinical study with another Investigation Medicinal Product
* Previous participation in another gene or cell therapy trial
* Any condition that would preclude subretinal surgery
* Complicating ocular and/or systemic diseases

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/26/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brittni Scruggs

Open for enrollment

Contact information:

Suzanne Wernimont

(507) 538-8119

wernimont.suzanne@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597117

Mayo Clinic Footer